Catalent Inc.

63.48
0.00 (0.00%)
At close: Dec 17, 2024, 9:00 PM
No 1D chart data available
Bid n/a
Market Cap 11.52B
Revenue (ttm) 4.41B
Net Income (ttm) -411.89M
EPS (ttm) -2.28
PE Ratio (ttm) -27.84
Forward PE 33.66
Analyst Hold
Ask n/a
Volume 13,674,041
Avg. Volume (20D) 2,227,006
Open 63.49
Previous Close 63.48
Day's Range 63.44 - 63.50
52-Week Range 42.11 - 63.50
Beta 1.16

About CTLT

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use...

Sector Healthcare
IPO Date Jul 31, 2014
Employees 17,000
Stock Exchange NYSE
Ticker Symbol CTLT

Analyst Forecast

According to 6 analyst ratings, the average rating for CTLT stock is "Hold." The 12-month stock price forecast is $63.5, which is an increase of 0.03% from the latest price.

Buy 0.00%
Hold 100.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Catalent Inc. is scheduled to release its earnings on Feb 7, 2025, before market opens.
Analysts project revenue of $1.10B, reflecting a 6.59% YoY growth and earnings per share of 0.11, making a -145.83% decrease YoY.
11 months ago
+9.74%
Catalent shares are trading higher after the compa... Unlock content with Pro Subscription